Sandbox Reserved 1791
From Proteopedia
(Difference between revisions)
Line 26: | Line 26: | ||
[[Image:Inactive v active residue.png|300 px|right|thumb| Figure 3: A zoomed in view of the Y279 residue in the Hinge Region of TSHR, showing the 6 angstrom move of Y279 during the activation of TSHR. Active TSHR is shown in green (PDB: 7t9i) and inactive TSHR is shown in pink (PDB: 7t9m).]] | [[Image:Inactive v active residue.png|300 px|right|thumb| Figure 3: A zoomed in view of the Y279 residue in the Hinge Region of TSHR, showing the 6 angstrom move of Y279 during the activation of TSHR. Active TSHR is shown in green (PDB: 7t9i) and inactive TSHR is shown in pink (PDB: 7t9m).]] | ||
In its resting state without TSH, TSHR is in the <scene name='95/952720/Inactivetshr/7'>inactive state</scene>, also considered the "down" state because the LRRD is pointing down. When TSH binds to TSHR, steric clashes between TSH and the cell-membrane cause TSHR to take on the <scene name='95/952720/Inactivetshr/6'>active or "up" state</scene>. During this transition, the extracellular LRD rotates 55° along an axis making it perpendicular to the cell membrane. This rotation is initiated by conformational changes within the <scene name='95/952720/Hinge_region_spin/3'>Hinge Region</scene>, specifically at the <scene name='95/952720/Hinge_region_residues/2'>TYR279 residue</scene>. Y279 moves 6 Å relative to I486, a residue located in the Transmembrane Region <ref name="Faust"/>. The active form is favored when <scene name='95/952719/Active_form/6'>TSHR is bound to TSH</scene>. The structure can be seen as straight. The same straight conformation is observed when TSHR is bound with M22. The inactive form is found when <scene name='95/952719/Inactive_form/7'>TSHR is bound with K1</scene> of TSHR is found when bound with K1. The overall structure of the molecule is bent when K1 is bound. | In its resting state without TSH, TSHR is in the <scene name='95/952720/Inactivetshr/7'>inactive state</scene>, also considered the "down" state because the LRRD is pointing down. When TSH binds to TSHR, steric clashes between TSH and the cell-membrane cause TSHR to take on the <scene name='95/952720/Inactivetshr/6'>active or "up" state</scene>. During this transition, the extracellular LRD rotates 55° along an axis making it perpendicular to the cell membrane. This rotation is initiated by conformational changes within the <scene name='95/952720/Hinge_region_spin/3'>Hinge Region</scene>, specifically at the <scene name='95/952720/Hinge_region_residues/2'>TYR279 residue</scene>. Y279 moves 6 Å relative to I486, a residue located in the Transmembrane Region <ref name="Faust"/>. The active form is favored when <scene name='95/952719/Active_form/6'>TSHR is bound to TSH</scene>. The structure can be seen as straight. The same straight conformation is observed when TSHR is bound with M22. The inactive form is found when <scene name='95/952719/Inactive_form/7'>TSHR is bound with K1</scene> of TSHR is found when bound with K1. The overall structure of the molecule is bent when K1 is bound. | ||
- | <scene name='95/952719/Active_form/5'>TextToBeDisplayed</scene> | ||
== Specific Residues and Interactions== | == Specific Residues and Interactions== | ||
There are two <scene name='95/952719/Specific_residues/6'>lysine residues</scene> in the binding pocket of TSHR that are the main contributors to the binding of the antibodies. The concave structure of the binding pocket allows a <scene name='95/952719/Lock_and_key/8'>tight interaction</scene> with the antibodies. These antibodies make tight interactions with a lot of intermolecular forces at play. <scene name='95/952719/K---e_interaction/8'>LYS 58</scene> interacts with Glu 118 on the antibodies to make a [https://www.nature.com/articles/s41598-018-31935-z salt bridge interaction]. <scene name='95/952719/K---d_interaction/9'>LYS 209</scene> interacts with Asp 111 on the antibodies to make a salt bridge interaction. Specifically, the two residues make an ionic interaction. The interaction is not close enough to make a hydrogen bond. Instead, the interaction between the Lys residues with the Asp or Glu residues is a salt bridge interaction. This is the main bond that holds these two molecules together. When in the inactive form, LYS 209 does not interact with any residue but LYS 58 has interaction with Glu 118 and this interaction pulls the molecule into the bent position. The salt bridge interaction between Lys and Glu is very specific. Lys was mutated with Arg and was expected to make the same salt bride interaction with Glu, however it make a completely different interaction. This new interaction favors a gain of function towards [https://my.clevelandclinic.org/health/articles/22489-human-chorionic-gonadotropin hCG] <ref name="Guillaume">Smits G, Govaerts C, Nubourgh I, Pardo L, Vassart G, Costagliola S. Lysine 183 and glutamic acid 157 of the TSH receptor: two interacting residues with a key role in determining specificity toward TSH and human CG. Mol Endocrinol. 2002 Apr;16(4):722-35. doi: 10.1210/mend.16.4.0815. PMID: 11923469. [DOI: 10.1210/mend.16.4.0815 https://pubmed.ncbi.nlm.nih.gov/11923469/]</ref>. | There are two <scene name='95/952719/Specific_residues/6'>lysine residues</scene> in the binding pocket of TSHR that are the main contributors to the binding of the antibodies. The concave structure of the binding pocket allows a <scene name='95/952719/Lock_and_key/8'>tight interaction</scene> with the antibodies. These antibodies make tight interactions with a lot of intermolecular forces at play. <scene name='95/952719/K---e_interaction/8'>LYS 58</scene> interacts with Glu 118 on the antibodies to make a [https://www.nature.com/articles/s41598-018-31935-z salt bridge interaction]. <scene name='95/952719/K---d_interaction/9'>LYS 209</scene> interacts with Asp 111 on the antibodies to make a salt bridge interaction. Specifically, the two residues make an ionic interaction. The interaction is not close enough to make a hydrogen bond. Instead, the interaction between the Lys residues with the Asp or Glu residues is a salt bridge interaction. This is the main bond that holds these two molecules together. When in the inactive form, LYS 209 does not interact with any residue but LYS 58 has interaction with Glu 118 and this interaction pulls the molecule into the bent position. The salt bridge interaction between Lys and Glu is very specific. Lys was mutated with Arg and was expected to make the same salt bride interaction with Glu, however it make a completely different interaction. This new interaction favors a gain of function towards [https://my.clevelandclinic.org/health/articles/22489-human-chorionic-gonadotropin hCG] <ref name="Guillaume">Smits G, Govaerts C, Nubourgh I, Pardo L, Vassart G, Costagliola S. Lysine 183 and glutamic acid 157 of the TSH receptor: two interacting residues with a key role in determining specificity toward TSH and human CG. Mol Endocrinol. 2002 Apr;16(4):722-35. doi: 10.1210/mend.16.4.0815. PMID: 11923469. [DOI: 10.1210/mend.16.4.0815 https://pubmed.ncbi.nlm.nih.gov/11923469/]</ref>. |
Revision as of 21:49, 20 April 2023
This Sandbox is Reserved from February 27 through August 31, 2023 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1765 through Sandbox Reserved 1795. |
To get started:
More help: Help:Editing |
Thyroid Stimulating Hormone Receptor (TSHR)
|
References
- ↑ 1.0 1.1 1.2 Faust B, Billesbolle CB, Suomivuori CM, Singh I, Zhang K, Hoppe N, Pinto AFM, Diedrich JK, Muftuoglu Y, Szkudlinski MW, Saghatelian A, Dror RO, Cheng Y, Manglik A. Autoantibody mimicry of hormone action at the thyrotropin receptor. Nature. 2022 Aug 8. pii: 10.1038/s41586-022-05159-1. doi:, 10.1038/s41586-022-05159-1. PMID:35940205 doi:http://dx.doi.org/10.1038/s41586-022-05159-1
- ↑ 2.0 2.1 Duan J, Xu P, Luan X, Ji Y, He X, Song N, Yuan Q, Jin Y, Cheng X, Jiang H, Zheng J, Zhang S, Jiang Y, Xu HE. Hormone- and antibody-mediated activation of the thyrotropin receptor. Nature. 2022 Aug 8. pii: 10.1038/s41586-022-05173-3. doi:, 10.1038/s41586-022-05173-3. PMID:35940204 doi:http://dx.doi.org/10.1038/s41586-022-05173-3
- ↑ Fokina, E.F., Shpakov, A.O. Thyroid-Stimulating Hormone Receptor: the Role in the Development of Thyroid Pathology and Its Correction. J Evol Biochem Phys 58, 1439–1454 (2022). [DOI:10.1134/S0022093022050143 https://doi.org/10.1134/S0022093022050143]
- ↑ Chen CR, McLachlan SM, Rapoport B. Thyrotropin (TSH) receptor residue E251 in the extracellular leucine-rich repeat domain is critical for linking TSH binding to receptor activation. Endocrinology. 2010 Apr;151(4):1940-7. doi: 10.1210/en.2009-1430. Epub 2010 Feb 24. PMID: 20181794; PMCID: PMC2851189. [DOI 10.1210/en.2009-1430 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851189/]
- ↑ Nunez Miguel R, Sanders J, Chirgadze DY, Furmaniak J, Rees Smith B. Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: a comparative structural study of protein-protein interactions. J Mol Endocrinol. 2009 May;42(5):381-95. Epub 2009 Feb 16. PMID:19221175 doi:10.1677/JME-08-0152
- ↑ Smits G, Govaerts C, Nubourgh I, Pardo L, Vassart G, Costagliola S. Lysine 183 and glutamic acid 157 of the TSH receptor: two interacting residues with a key role in determining specificity toward TSH and human CG. Mol Endocrinol. 2002 Apr;16(4):722-35. doi: 10.1210/mend.16.4.0815. PMID: 11923469. [DOI: 10.1210/mend.16.4.0815 https://pubmed.ncbi.nlm.nih.gov/11923469/]
- ↑ 7.0 7.1 Chiovato L, Magri F, Carlé A. Hypothyroidism in Context: Where We've Been and Where We're Going. Adv Ther. 2019 Sep;36(Suppl 2):47-58. doi: 10.1007/s12325-019-01080-8. Epub 2019 Sep 4. PMID: 31485975; PMCID: PMC6822815. [DOI: 10.1007/s12325-019-01080-8 https://pubmed.ncbi.nlm.nih.gov/31485975/]